Investors & Media

Corporate Profile

With its acquisition of Lung Therapeutics, Aileron is shifting its disease focus to orphan pulmonary and fibrosis indications. Aileron intends to advance Lung’s pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01, for loculated pleural effusion (LPE).

Data Provided by Refinitiv. Minimum 15 minutes delayed.

  • May 15, 2024
    Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
  • May 6, 2024
    Aileron Therapeutics to Present at Two Upcoming Investor Conferences
  • May 3, 2024
    Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million


  • May 20, 2024 at 4:30 PM EDT

    H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

    Read More
  • May 13, 2024 at 12:00 PM EDT

    Citizens JMP Life Sciences Conference

    Read More